My Companies
Notification
Account
Log Out
Login
Cipla signed an exclusive license and supply agreement with SBP Group for potential HER2 bispecific ADC TQB2102, covering development and commercialisation in India, South Africa and five emerging markets. Cipla will manage local development and approvals, while CTTQ manufactures and supplies the therapy, which has three Chinese Breakthrough Therapy Designations.
Cipla Receives VAI Classification For InvaGen New York Inspection
Cipla Receives Seven Form 483 Observations At Pithampur Facility
Cipla Receives US FDA Approval For Generic Advair Diskus Inhaler
Cipla Appoints Dinesh Jain Global CFO As Ashish Adukia Moves To Internal Role